Hair loss is your gain, Veradermics (NYSE: MANE) stock surges 17% on positive hair loss trial data

Veradermics, Incorporated (NYSE: MANE) shares rose 17% Monday after the company reported positive topline results from its Phase 2/3 clinical trial evaluating VDPHL01, an oral treatment for male pattern hair loss.

The trial, known as Study ’302’, enrolled 519 patients and met all primary and key secondary endpoints with statistical significance. VDPHL01, an extended-release minoxidil formulation, demonstrated a mean increase in non-vellus target area hair count of 30.3 hairs/cm² with once-daily dosing and 37.7 hairs/cm² with twice-daily dosing, compared to placebo.

Approximately 79.3% of patients receiving once-daily treatment and 86.0% receiving twice-daily treatment reported improvement in patient-reported outcomes versus 35.6% of placebo patients. Additionally, 48.4% of once-daily patients and 58.1% of twice-daily patients reported moderate or marked improvement.

The treatment showed statistically significant improvement in hair growth at Month 2, the earliest time point evaluated in the trial. Investigators graded 72.0% of once-daily patients and 81.7% of twice-daily patients as having improved hair growth.

VDPHL01 was generally well tolerated through Month 6, with overall adverse event rates similar to placebo. The study reported no treatment-related serious adverse events and no adverse events of special interest of cardiac origin. Discontinuation rates for VDPHL01 were lower than placebo.